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years later.
Methods: One hundred and eleven participants (64% male, mean age
30±8 years) one year following hamstring-tendon ACLR underwent
examination of knee structure (3T MRI), function (battery of hop tests
and one-leg rise test) and symptoms (Knee injury Osteoarthritis Out-
come Score [KOOS], with activities of daily living subscale excluded due
to large ceiling effect). Patellofemoral and tibiofemoral compartments
were assessed on MRI for BMLs, cartilage lesions and osteophytes by an
experienced musculoskeletal radiologist (AG) using the MRI Osteo-
arthritis Knee Score (MOAKS). Two years following baseline assessment
(ie. three years post-ACLR), participants free of further injury/surgery
since the primary ACLR (n¼98) were recontacted to complete the KOOS.
Multivariate regression analyses were used to evaluate whether com-
partment-speciﬁc MRI features or any functional test was associated
with three year KOOS outcome (adjusted for age, gender, BMI and
baseline KOOS score). Ninety-three of the 98 eligible participants (95%)
completed the KOOS at follow-up.
Results: Baseline patellofemoral BMLs, cartilage lesions and osteo-
phytes were observed in 20 (22%), 43 (46%), and 43 (46%) knees,
respectively. The corresponding rates of tibiofemoral MRI features were
29 (31%), 38 (41%), and 41 (44%). At baseline, 57 (61%) and 36 (39%) of
the 93 participants had a limb-symmetry index (LSI) 90% for the hop
for distance and side-hop test, respectively, while 54 (58%) performed
>22 one-leg rises (common cut-off). All KOOS subscale scores improved
from baseline to follow-up (improvement range: KOOS-Pain¼4 points
to KOOS-QOL¼11 points). The presence of a patellofemoral cartilage
lesion at baseline was the only MRI feature that predicted aworse KOOS
outcome at follow-up (all KOOS-subscales: b¼-0.2, p<0.01). Performing
<22 one-leg rises at baseline predicted KOOS-QOL score at follow-up
(b¼-0.2, p¼0.03). No other functional test predicted knee symptoms.
Conclusions: The presence of a cartilage lesion in the patellofemoral
compartment and a functional deﬁcit assessed with the one-leg rise test
have prognostic implications for symptomatic outcomes following
ACLR. The modiﬁable nature of the one-leg rise test suggests that
deﬁciencies in this functional task provide an attractive target for post-
operative rehabilitation. Given the association between patellofemoral
cartilage lesions and knee symptoms, rehabilitation programs post-
ACLR may also need to have a greater emphasis on the patellofemoral
joint.
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THE DIAGNOSTIC PERFORMANCE OF CLINICAL EXAMINATION
MEASURES, LOCATION OF PAIN AND PAIN WITH ACTIVITIES IN
IDENTIFYING KNEES WITH RADIOGRAPHIC PATELLOFEMORAL
JOINT OSTEOARTHRITIS
J. Stefanik y, D. Felson y, R. Duncan z, G. Peat x. yBoston Univ., Boston, MA,
USA; zNewcastle Univ., Newcastle, United Kingdom; xKeele Univ., Keele,
United Kingdom
Purpose: Patellofemoral joint (PFJ) osteoarthritis (OA) is highly preva-
lent and a common source of symptoms in individuals with knee OA.
Biomechanical and rehabilitation treatments for PFJ and tibiofemoral
joint (TFJ) OA may differ, making the identiﬁcation of individuals with
PFJ OA from clinical exam and pain patterns important. Anterior knee
pain (AKP) and pain with stair climbing are widely believed to be
indicative of a PFJ disorder. However, we previously reported that they
have poor diagnostic utility to identify MRI-deﬁned PFJ OA in a large
cohort study of older individuals. Radiographic assessment using a
skyline view is the gold standard method to identify knees with PFJ OA.
Clinical exam measures in addition to pain location and with may
improve the ability to identify individuals with PFJ OA. The purpose of
this study was to externally validate our previous ﬁndings in a separate
cohort with PFJ OA deﬁned by plain radiography as the reference
standard and to explore the diagnostic utility of measures from the
clinical exam.
Methods: The Clinical Assessment of the Knee Study is a large pro-
spective study of knee pain in the general population in the United
Kingdom. Data was collected from 2002-2006 and subjects were >50
years of age with knee pain. The presence of PFJ crepitus during knee
ﬂexion and extension and pain with PFJ compression were assessed.
Subjects identiﬁed painful areas around their knee on a knee pain map,
which was used to deﬁne AKP. Subjects reported pain with stairs and
walking on level ground (its absence might rule in PFJ pathology) using
the WOMAC. Radiographs were used to deﬁne the compartment(s) ofthe knee affected by OA. Three views of the knee were obtained:
weight-bearing postero-anterior (PA) semiﬂexed, skyline and lateral
views. A Kellgren and Lawrence (KL) score was assigned to the PA and
skyline views. TFJ OA was deﬁned by a KL score 2 on the PA view and/
or the presence of deﬁnite osteophytes on the posterior tibia on the
lateral view. PFJ OA was deﬁned by a KL score 2 on the skyline view
and/or the presence of a deﬁnite superior and/or inferior osteophyte on
the patella on the lateral view. Knees were categorized as having no OA,
isolated PFJ OA, isolated TFJ OA and mixed OA. In knees with mixed OA,
we determinedwhich compartment had the greatest OA severity. Knees
with more severe PFJ OA were included in the isolated PFJ group (the
same was done for TFJ OA). If the severity of OAwas the same in the PFJ
and TFJ these knees were removed. We determined the sensitivity (Sn),
speciﬁcity (Sp), positive and negative predictive values (PPV and NPV),
and positive likelihood ratio (LRþ; Sn/1-Sp) for PFJ compression test, PFJ
crepitus, AKP, pain with stairs ( minimal), absence of pain with
walking on level ground ( minimal) and the combination of these
measures in identifying knees with PFJ OA from knees with TFJ OA or no
OA.
Results: 745 knees (one knee per person) were included in the study.
The mean (sd) age and bmi were 65.2 (8.6) and 29.6 (5.2), respectively;
55% were female. The prevalence of no OA, isolated PFJ OA, isolated TFJ
OA and mixed was 236 (32%), 178 (24%), 30 (4%) and 301 (40%),
respectively. Of 301 knees with mixed OA, 57 and 115 had more severe
PFJ and TFJ OA, respectively; 129 had the same severity. Nomeasure had
high Sn and Sp (see table). Painwith stairs had the greatest Sn (90%) but
poor Sp (15%). The combination of deﬁnite crepitus with no pain with
walking on level ground had the greatest Sp (96%), PPV (53%) and LRþ
(1.75) but poor Sn (7%). No test or combination of tests had a LRþ
greater than 2.
Conclusions: Among persons aged over 50 years with knee pain, typical
clinical exam ﬁndings and knee pain patterns that are commonly
thought to represent underlying PFJ pathology do not discriminate
knees with PFJ OA from knees without OA or TFJ OA.
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HIGHER BODY FAT CONTENT IS RELATED TO SYNOVIAL LEPTIN BUT
NOT TO SYNOVIAL EFFUSION IN SYMPTOMATIC KNEE
OSTEOARTHRITIS
J. Calvet, C. Orellana, N. Navarro, C. Galisteo, J. Gratacos, M. Larrosa. Parc
Taulí Sabadell Hosp. Univ.ri, Sabadell, Spain
Purpose: Obesity and especially body fat content appears to play a role
in the development and especially in the progression of osteoarthritis
(OA). Leptin is an adipokine involved in body weight regulation and
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A324usually shows higher levels in obese patients. Leptin has proin-
ﬂammatory effects and has been implicated in OA physiopathology.
Objective: To evaluate the relationship between body fat content with
the amount of synovial ﬂuid as a surrogate marker of inﬂammation and
with levels of synovial ﬂuid leptin in knee OA.
Methods: Patients aged 50 years or more with symptomatic osteo-
arthritis of the knee and joint effusion, Kellgren-Lawrence II-III. Dem-
ographics, disease duration and percentage of body fat (PBF) were
assessed. Percentage of body fat was determined by bio-electrical
impedance. Knee ultrasound (US) was performed evaluating and
measuring the presence of effusion and at the suprapatellar midline.
After US measurement joint aspiration was performed; all patients
were evaluated approximately at the same time of the day. Synovial
leptin levels were analyzed using a Human leptin ELISA kit (Bio-
compare, California, USA).
Results: Seventy consecutive female patients with symptomatic knee
OA and Kellgren-Lawrence II-III were included, age 65 ±7.8 years, dis-
ease duration of symptoms 66 ±49.5 mo (12-200). Mean BFP was 42.34
±5.11%. Patients were categorized into two groups based on BFP so that
those with levels above the mean and median values (n¼ 36) were
compared with the rest of the sample (n¼34). Mean synovial ﬂuid
measurement was 9.59 ±2.79 mm. Mean level of leptin in synovial ﬂuid
was 76.76 ±38.66 ng/mL. Patients in the higher BFP group had similar
amount of synovial effusion compared with those without such a high
percentage (9.4 ±2.4 vs. 9.75 ±3.2 mm). However, patients with BFP
above the mean and median values showed signiﬁcantly higher syno-
vial leptin levels than those with values below (88.47 ±46.8 vs. 60.24
±19.5 ng/mL, p <0.005).
Conclusions: Higher synovial leptin levels were observed in patients
with the highest body fat percentage as measured by bio-electrical
impedance. On the other hand, synovial effusion did not appear to be
linked to body fat content, indicating that body fat could be more
related to metabolic abnormalities than to clinical signs of inﬂamma-
tion.
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SYSTEMIC INFLAMMATION AND PAINFUL JOINT BURDEN IN
OSTEOARTHRITIS: A MATTER OF SEX
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Purpose: Sex has a signiﬁcant effect on osteoarthritis (OA) prevalence
and severity, and women with OA often report greater pain than men
with OA. Pain is the principal driver of health care use in this pop-
ulation. Importantly, there is a connection between pain and inﬂam-
mation. While OA has not traditionally been considered a systemic joint
disease, evidence suggests that systemic factors may play a contributing
role in its pathogenesis and symptoms. The presence of multiple
symptomatic joints among many with OA further suggests potentially
underlying systemic mechanisms. Higher systemic concentrations of C-
reactive protein (CRP) among OA populations compared to controls
have been reported (CRP is a marker of inﬂammation), and a recent
review suggested low-grade inﬂammation may play a greater role in
symptoms than radiographic changes in OA. Sex differences in systemic
inﬂammation may explain sex differences in OA symptoms. However, it
may also be that for similar levels of inﬂammation, women report worse
pain than men. In this study, we investigated the association between
serum levels of CRP and the extent of painful joint involvement among
individuals with end stage hip/knee OA, and whether the association
differs between sexes.
Methods: Serum concentrations of CRP and cartilage oligomeric matrix
protein (COMP- a proxy for disease burden) were determined by ELISA
in 203 patients (115 females, 88 males) scheduled for total hip or knee
replacement surgery for OA. Individuals reporting inﬂammatory
arthritis were excluded. Patients completed a health questionnaire, and
indicated on a homunculus all joints that were painful/problematic on
most days for at least a month in the past 12 months. A count (not
including the surgical joint) was developed (range: 0 to 21). Also elicited
were age, sex, height and weight (used to calculate body mass index(BMI)), and comorbidities. Negative binomial regression was used to
investigate the association between painful joint count (model out-
come) and serum CRP concentrations, adjusting for age, sex, BMI,
comorbidity count and serum COMP concentration. An interaction
between sex and these biomarkers was tested. In a sensitivity analysis,
all individuals reporting conditions associated with metabolic syn-
drome were excluded from analysis (high blood pressure, diabetes,
heart disease and high cholesterol). For regression analyses, concen-
tration values were log transformed.
Results: Mean age: 66 years among women (>96% were 50), 64
among men. Women had higher mean joint count (4.6 vs 2.5, p<0.001;
4þ joints reported by 42% women, 28%men). 51% of womenwere obese
vs 36% in men (p¼0.06). Median CRP concentration was higher in
women (18.7 mg/ml vs 9.3, p¼0.003). From adjusted analyses, the effects
of both CRP and COMP were modiﬁed by sex (interaction terms:
p<0.001 and ¼0.016, respectively). Increasing concentration of CRP was
associated with greater painful joint burden among women, but not
men (Count ratio (CR) of interaction term: 1.4 (95% CI: 1.2, 1.6); main
effect: 0.9 (0.8, 1.0)). Results from the sensitivity analysis were con-
sistent (CR of interaction: 1.5 (1.1, 1.9); main effect: 0.81 (0.6, 1.0).
Conclusions: This work suggests that there may be a dose-response
association between painful joint burden in OA and systemic inﬂam-
mation, and it appears the association is sex-speciﬁc. These ﬁndings
create a potential opportunity to better risk-stratify women and men
with OA pain, with a goal to tailoring assessment, treatment, and/or
education strategies to optimize OA outcomes. In addition, given that
high systemic concentration of CRP has been identiﬁed as a risk factor
for diabetes and cardiovascular disease onset, these ﬁndings suggest
that those with greater joint burden may be an OA subgroup at greater
risk of comorbid disease onset, particularly women.
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LOW-DOSE SOLUMATRIX MELOXICAM DEMONSTRATES LOW
SYSTEMIC EXPOSURE AND EFFICACY IN PATIENTS WITH
OSTEOARTHITIS PAIN IN CLINICAL STUDIES
R. Altman y, M. Hochberg z, A. Gibofsky x, L. Kwong k, C. Young ¶. yDavid
Geffen Sch. of Med., Univ. of California Los Angeles, Los Angeles, CA, USA;
zUniv. of Maryland Sch. of Med., Baltimore, MD, USA; xHosp. for Special
Surgery, New York, NY, USA; kDept. of Orthopaedic Surgery, Harbor-
UCLA Med. Ctr., Los Angeles, CA, USA; ¶ Iroko Pharmaceuticals, LLC,
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Purpose: NSAIDs are frequently prescribed for the management of OA
pain. Investigational, low-dose SoluMatrix® meloxicam, manufactured
using SoluMatrix Fine Particle TechnologyTM, is being developed for
management of osteoarthritis pain, providing lower systemic exposure
than current commercially available meloxicam drug products to
potentially minimize the risk of NSAID dose-related adverse events
(AEs). Clinical studies have evaluated the pharmacokinetics (PK), efﬁ-
cacy, and safety of low-dose SoluMatrix meloxicam.
Methods: A phase 1 pharmacokinetic 4-period, 4-sequence crossover
study in healthy adults aged 18 to 55 years evaluated the PK properties
and safety of single doses of SoluMatrix meloxicam 5 mg (under fasted
conditions), SoluMatrix meloxicam 10 mg (under fasted and fed con-
ditions), and conventional meloxicam 15-mg tablets (Mobic®; Boeh-
ringer Ingelheim; under fasted conditions). Blood samples for PK
assessment were collected pre-dose through 96 h post-dose. Separately,
a phase 3 randomized, double-blind, placebo-controlled study enrolled
adults 40 years of age with radiographically conﬁrmed (Kellgren-
Lawrence grade II-III) hip or knee OA. Eligible patients were chronic
NSAID and/or acetaminophen users with a baseline WOMAC pain
subscale score 40 mm (based on 100-mm Visual Analog Scale) and a
documented OA pain ﬂare (15-mm increase in WOMAC pain subscale
score following washout of prior analgesics). Patients (N ¼ 403) were
randomized to receive once-daily treatment with SoluMatrix melox-
icam 5mg (n¼ 139), SoluMatrix meloxicam 10mg (n¼ 130), or placebo
(n ¼ 134). The primary efﬁcacy parameter was the mean change from
baseline in WOMAC pain subscale score at week 12.
Results: In the PK study, 28 participants were enrolled and 25 partic-
ipants completed the study. SoluMatrix meloxicam 10 mg attained
similar mean peak plasma meloxicam levels ± SD compared with con-
ventional meloxicam 15-mg tablets (1.25±0.25 mg/mL vs 1.29±0.42 mg/
mL, respectively; under fasted conditions; Table). Both SoluMatrix
meloxicam 5 mg and 10 mg achieved a more rapid median time to peak
plasma meloxicam levels under fasted conditions than conventional
